Thermo and Cellectis shake hands over Talen gene editing tech for biopharmas

By Gareth Macdonald

- Last updated on GMT

Thermo  licenses gene editing tech for biopharmas from Cellectis

Related tags Dna Gene Protein Thermo fisher

Thermo Fisher Scientific has licensed rights to gene editing technology for bioproduction applications that it claims targets DNA more precisely and reliably than current approaches.  

The deal saw Thermo Fisher obtain rights to market customisable DNA targeting and cutting enzymes – known as transcription activator-like effector-nucleases - for R&D and bioproduction applications from French life sciences firm Cellectis.

Helge Bastian, general manager and vice president of synthetic biology at Thermo said “The ability of TAL effectors to bind to DNA with unprecedented precision and reliability makes this technology invaluable to researchers looking to edit genomes and control gene activity​.”

In nature TALEs – or transcription activator-like effectors – are proteins secreted by Xanthomonas​ bacteria that bind plant DNA and modulate gene expression to allow the bug to more easily colonize the infected host.

This ability to bind DNA is what makes TALEs useful for gene editing particularly because, unlike zinc-finger nucleases (ZFN) which are also used to edit DNA,​ the protein sequence responsible for binding is simple and can be readily modified to target specific sequences​.

The licensed tech – which will be sold by Thermo’s Life Technologies division – was licensed by Cellectis from the University of Minnesota in 2011.

The Paris firm – which develops chimeric antigen receptor T-cells (CARTs) for therapeutic applications – retains rights to use the technology for in-house R&D, plant biotechnology and use with T cells.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more